ロード中...
A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
Pancreatic cancer is predominantly lethal, and is primarily treated using gemcitabine, with increasing resistance. Therefore, novel agents that increase tumor sensitivity to gemcitabine are needed. Histone deacetylase (HDAC) inhibitors are emerging therapeutic agents, since HDAC plays an important r...
保存先:
| 出版年: | Sci Rep |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5278546/ https://ncbi.nlm.nih.gov/pubmed/28134290 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep41615 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|